16 March 2018 - Becomes the first immunotherapy recommended for urothelial cancer after chemotherapy.

Certain bladder cancer patients in England will be able to get access to MSD's blockbuster Keytruda (pembrolizumab) following a go-ahead from the UK’s cost-effectiveness watchdog.

NICE has ruled that Keytruda can be made available as an option via the Cancer Drugs Fund for treating locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy.

As per terms of the recommendation, the medication should be stopped at two years of uninterrupted treatment, or earlier in the event of disease progression.

Read PM Live article